Lilly presented Phase III data for Jaypirca (pirtobrutinib) at the European Hematology Association (EHA) 2026 annual meeting in Stockholm, demonstrating for the first time that a three-drug combination can outperform a venetoclax-containing control regimen in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).
While the data are promising and gives Lilly an edge in CLL/SLL, the window for the US drugmaker to capitalize...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
